Get the latest news from Nutaria
The next experiment is on the way
Nutaria is advancing into a pivotal research stage with a large-scale therapeutic window experiment in rodent models. This carefully formulated study will help pinpoint the optimal dose and timing for our Parkinson’s treatment. By gathering a comprehensive range of data—including tissue analysis and video recordings of behavioral effects—this study will provide critical insights into how our drug interacts with the brain. The results will play a key role in shaping our approach to clinical trials, bringing us one step closer to developing an effective therapy for Parkinson’s disease.
May, 2024
We are proud to participate in the Biomed 2024 convention, which will be held on May 21th at the David Intercontinental Hotel in Tel Aviv.
See you at the Startup Pavilion!
April, 2024
Nutaria has completed two consecutive animal studies, validating the targeted delivery of its active ingredients. Conducted by an independent European preclinical Contract Research Organization (CRO), these studies have demonstrated the effective nasal delivery of Nutaria's nanoparticles to key brain structures in a sample of 52 rats.
June, 2023
Nutaria was selected among the top 10 European companies to participate in the prestigious EIT FAN Food-tech Food as Medicine accelerator program. Nutaria was accepted to the program at the Technion, Israel's Institute of Technology. The program participants get mentorship from leading corporations and specialists in the food tech industry, nutraceutical development, and go-to-market strategy.
May, 2023
We are proud to participate in the Biomed 2023 convention, which will be held on May 18th at the David Intercontinental Hotel in Tel Aviv.
Our presentation will explore novel solutions in targeted functional food delivery to various nutritional needs, focusing on cognitive and brain health support.
See you there!
September, 2022
Mind-blowing results from Nutaria’s first in vitro POC demonstrated project.
This in vitro study was performed by a third party preclinical CRO with the help of Nutaria in providing cultures of neuroectodermal humane cell lines. Results have shown that cells that express receptors for Nutria's coating ingredients internalized curcumin much more effectively, as can be seen in phosphorylated cells.
May, 2021
Nutaria was accepted to the prestigious innovation Lab program at IFF-DuPont's Israel food tech incubator.
The Israeli Innovation Authority supports this incubator, a harboring facility for Israel's future Biotech industry startups.
This recognition by IFF DuPont, a major international player in food ingredients and a stakeholder at Nutaria, is a source of pride for our team.
